Aurobindo Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Khandelwal Laboratories operates in India?s pharmaceutical industry with a presence in both oncology and non-oncology branded formulations. The non-oncology portfolio comprises 23 brands across 67 stock-keeping units (SKUs), along with nine products in the pipeline where anti-infective as well as pain management are the major portfolios. The business generated a turnover of Rs 113.53 crore in FY2024-25 with an EBITDA of Rs 28.99 crore.

The transaction was signed and completed on 1 January 2026. Under the agreement, Auro Pharma has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories as a going concern on a slump-sale basis. The acquisition includes inventory, intellectual property, employees, contracts, and other associated assets. The total cash consideration for the transaction is Rs 325 crore.

The acquisition is expected to strengthen the company?s pain management and anti-infective portfolio, complementing its existing offerings and supporting expansion in the domestic market.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company?s consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.

Powered by Capital Market - Live News

Auro Pharma (Auro Pharma), a wholly owned subsidiary of Aurobindo Pharma at its meeting held today i.e. 01 January 2026 has approved the acquisition of non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis through a Business Transfer Agreement (BTA).

Powered by Capital Market - Live News

Aurobindo Pharma announced that pending receipt of state government approval for setting up a captive solar power plant, the required investment for acquiring 26% in Swarnaakshu Solar Power will be completed on or before 31 March 2026, subject to the receipt of approval from the concerned state government.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1198.8, down 0.61% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 25948.55. The Sensex is at 84699.55, down 0.4%.Aurobindo Pharma Ltd has eased around 1.43% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 1.26% in last one month and is currently quoting at 22684.65, down 0.37% on the day. The volume in the stock stood at 2.55 lakh shares today, compared to the daily average of 6.38 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 1202.3, down 0.37% on the day. Aurobindo Pharma Ltd tumbled 7.66% in last one year as compared to a 9.74% rally in NIFTY and a 2.76% fall in the Nifty Pharma index.

The PE of the stock is 34.66 based on TTM earnings ending September 25.

Powered by Capital Market - Live News